Loading
Eric Venker takes a $75K salary, but Roivant Sciences Ltd.'s DEF 14A reports $24.4M in total compensation for FY2026. The largest component was $20.2M in other compensation. Most of the gap was $20.2M reported as other compensation. That’s up 0% from FY2025. Source: SEC DEF 14A.
In fiscal year 2026, Eric Venker, President and Immunovant CEO of Roivant Sciences Ltd. (ROIV), received total compensation of $24.4 million.
Eric Venker's compensation breakdown includes: base salary of $75K, bonus of $1.9 million, stock awards valued at $2.3 million, and other compensation of $20.2 million.
Compared to fiscal year 2025, Eric Venker's total compensation increased 0% from $24.4 million to $24.4 million.
Roivant Sciences Ltd.'s top 5 named executive officers received combined total compensation of $156.3 million in fiscal year 2026.
The named executive officers disclosed in Roivant Sciences Ltd.'s 2026 proxy statement are:Matthew Gline (Chief Executive Officer) with total compensation of $3.1 million, Frank Torti (President and Vant Chair) with total compensation of $123.3 million, Eric Venker (President and Immunovant CEO) with total compensation of $24.4 million, Richard Pulik (Chief Financial Officer) with total compensation of $4.2 million, and Mayukh Sukhatme (President and Chief Investment Officer) with total compensation of $1.3 million.
Eric Venker, President and Immunovant CEO of Roivant Sciences Ltd. (ROIV), received $24,400,210 in total compensation for FY2026, up 0.0% from the prior year. Other compensation of $20,163,986 was the largest component. Figures come from Roivant Sciences Ltd.'s DEF 14A 0001140361-26-029955 filed 29 Jul 2026.
Source Filing
Executive Record
Eric Venker
President and Immunovant CEO
Reported Pay
$24.4MSummary compensation table total · FY2026
Findings
Reviewing FY2026 compensation of $24.4M against +73% shareholder return and the latest filing-backed pay disclosures.
Reported pay changed 0%; spread versus stock performance is pending computation.
Evidence is sourced from the latest executive compensation filing and return series for ROIV.
Roivant Sciences Ltd. (ROIV) — Key Facts
Last updated Aug 27, 2026 · DEF 14A filed Jul 29, 2026
| CEO | Eric Venker, President and Immunovant CEO |
|---|---|
| Fiscal year | FY2026 |
| Total compensation | $24.4M |
| Base salary | $75K |
| Stock awards | $2.3M |
| Other compensation | $20.2M |
| Year-over-year change | +0% |
| Source | DEF 14A, 2026-07-29 |
Eric Venker's base salary at Roivant Sciences Ltd. was $75,000. Total compensation was $24,400,210 in fiscal year 2026. Most of the gap was $20,163,986 reported as other compensation. Figures come from Roivant Sciences Ltd.'s DEF 14A 0001140361-26-029955 filed 29 Jul 2026.
Eric Venker's base salary at Roivant Sciences Ltd. is $75,000 per year as of fiscal year 2026. The larger reported compensation figure of $24,400,210 is mostly $20,163,986 reported as other compensation. Figures come from Roivant Sciences Ltd.'s DEF 14A 0001140361-26-029955 filed 29 Jul 2026.
Roivant Sciences Ltd.'s CEO, Eric Venker, earned $24,400,210 in total compensation for fiscal year 2026. Base salary was $75,000, and most of the remaining total was $20,163,986 reported as other compensation. Figures come from Roivant Sciences Ltd.'s DEF 14A 0001140361-26-029955 filed 29 Jul 2026.
Reading filings for ROIV...
Reading the latest proxy statement
Calculating CEO-to-worker ratio
Checking insider sales and trading plans